AbCellera Biologics Inc (NASDAQ: ABCL) kicked off on Tuesday, down -5.85% from the previous trading day, before settling in for the closing price of $2.05. Over the past 52 weeks, ABCL has traded in a range of $1.89-$4.75.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 376.38%. While this was happening, its average annual earnings per share was recorded -10.53%. With a float of $223.58 million, this company’s outstanding shares have now reached $295.76 million.
Let’s determine the extent of company efficiency that accounts for 596 employees. In terms of profitability, gross margin is -188.19%, operating margin of -1091.65%, and the pretax margin is -695.0%.
AbCellera Biologics Inc (ABCL) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of AbCellera Biologics Inc is 24.97%, while institutional ownership is 37.05%.
AbCellera Biologics Inc (ABCL) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.14 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -10.53% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -9.14% during the next five years compared to -107.74% drop over the previous five years of trading.
AbCellera Biologics Inc (NASDAQ: ABCL) Trading Performance Indicators
Take a look at AbCellera Biologics Inc’s (ABCL) current performance indicators. Last quarter, stock had a quick ratio of 9.81. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 19.95.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.55, a number that is poised to hit -0.14 in the next quarter and is forecasted to reach -0.65 in one year’s time.
Technical Analysis of AbCellera Biologics Inc (ABCL)
Looking closely at AbCellera Biologics Inc (NASDAQ: ABCL), its last 5-days average volume was 4.48 million, which is a jump from its year-to-date volume of 4.13 million. As of the previous 9 days, the stock’s Stochastic %D was 18.81%. Additionally, its Average True Range was 0.18.
During the past 100 days, AbCellera Biologics Inc’s (ABCL) raw stochastic average was set at 2.23%, which indicates a significant decrease from 5.63% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 61.14% in the past 14 days, which was lower than the 68.22% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.69, while its 200-day Moving Average is $2.79. However, in the short run, AbCellera Biologics Inc’s stock first resistance to watch stands at $2.08. Second resistance stands at $2.23. The third major resistance level sits at $2.32. If the price goes on to break the first support level at $1.84, it is likely to go to the next support level at $1.75. Should the price break the second support level, the third support level stands at $1.60.
AbCellera Biologics Inc (NASDAQ: ABCL) Key Stats
The company with the Market Capitalisation of 575.12 million has total of 297,988K Shares Outstanding. Its annual sales at the moment are 28,830 K in contrast with the sum of -162,860 K annual income. Company’s last quarter sales were recorded 5,050 K and last quarter income was -34,210 K.
